Durán-Salgado MB, Garro-Almendaro AK, Rubio-Guerra AF

Language: Spanish
References: 15
Page: 395-401
PDF size: 535.83 Kb.

ABSTRACT

Background: Hypertension and diabetes usually cluster in the same patient, antihypertensive agents modify that association. However, there are few studies about their combinations.
Objective: To evaluate the effect of two combinations of losartan, with amlodipine or with hydrochlorothiazide, on glycemic and lipid values, in hypertensive subjects.
Methods: A cross-sectional and comparative study done with hypertensive patients, who were randomized in 2 groups; group LA received losartan/amlodipine (100/5 mg) once a day, whereas LH group received losartan hydrochlorothiazide (100/12.5 mg) once a day, for 3 months. In all of them fasting serum glucose, and a lipid profile were performed at the beginning and end of the study, statistical analysis was performed with ANOVA.
Results: All patients experienced a significant reduction of blood pressure to same extent (LA 155/94 to 123/79, LH 157/92 to 124/78 mmHg, p›0.05). In the LA group, serum glucose levels shown a significantly reduction, whereas in the LH group those values shown an increase, (LA 116 to 87 mg/dL, LH 120 to 126 mg/dL, p=0.002), in 3 patients those values went over the diagnostic figure of 125 mg/dL. Triglyceride levels decreased in the LA group, and rose in the LH patients, (203 to 174 mg/dL vs 208 to 210 mg/dL, p=0.02). We did not find significant changes in other lipoproteins.
Conclusions: Both combinations decrease blood pressure values to same extent, however, LA combination shown favorable effects that reduce the metabolic risk in hypertensive patients.

REFERENCES

1. Rubio-Guerra AF, Rodríguez-López L, Lozano-Nuevo JJ, Vargas-Ayala G y col. Prevalencia de tolerancia a la glucosa anormal en pacientes hipertensos. Rev Med IMSS 2014;52:404-407.

2. Rubio-Guerra AF, Durán-Salgado MB. Insulina, sistema renina-angiotensina-aldosterona y disfunción endotelial. Rev Med IMSS 2011;49:581-584.

3. Rubio-Guerra AF, Cabrera-Miranda JL, Vargas-Robles H, Maceda-Serrano A, et al. Correlation between Levels of Circulating Adipokines and Adiponectin/Resistin Index with Carotid Intima-Media Thickness in Hypertensive Type 2 Diabetic Patients. Cardiology 2013;125:150-153.

4. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014;19:5-13.

5. Ueda S, Morimoto T, Ando S, Takishita S, et al. A randomized controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) study. BMJ Open 2014;4:e004576. doi: 10.1136/bmjopen-2013-004576.

6. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014;6:517-530.

7. Dahlöf B, Sever PS, Poulter NR, Wedel H, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366: 895-906.

8. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al, for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816.

9. James PA, Oparil S, Carter BL, Cushman WC, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520.

10. Task Force for the management of arterial hypertension of the European Society of Hypertension; Task Force for the management of arterial hypertension of the European Society of Cardiology. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Blood Press 2013;22:193-278.

11. Rubio-Guerra AF, Castro-Serna D, Elizalde-Barrera CI, Ramos-Brizuela LM. Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. Integr Blood Press Cont 2009;2:55-62.

12. Bakris GL, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-2597.

13. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodríguez-Lopez L, et al. Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension. Ther Adv Cardiovasc Dis 2011;5:193-197.

14. Rubio-Guerra AF, Vargas-Robles H, Lozano-Nuevo JJ, Elizalde-Barrera CI, et al. Beneficial effect of combination therapy with an angiotensin-converting enzyme inhibitor plus verapamil on circulating resistin levels in hypertensive patients with type-2 diabetes. Exp & Clin Cardiol 2012;17:202-204.

15. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, et al. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011;25:346-353.